Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries

Table 8

Other tumor types recorded in bronchial NET patients diagnosed, treated, or followed-up at our institution from 1^st January 1995 to 31^st December 2015 ().

Non-NET tumors that occurred in patients with a bronchial NET	Number of patients (and %)
Total number of patients with other tumors	14 (30.4%)
Total number of other tumors	17 (37.0%)
(i) Before the diagnosis of bronchial NET; (ii) Synchronous tumors; (iii) Metachronous tumors	(i) 5/17 (29.4%); (ii) 8/17 (47.1%); (iii) 4/17 (23.5%)
Tumor types
(i) Cheek squamous cell carcinoma; (ii) Colorectal cancer; (iii) Metastatic squamous cell carcinoma of unknown primary; (iv) Lung squamous cell carcinoma; (v) Renal cancer; (vi) Salivary gland benign cystic tumor; (vii) Lung adenocarcinoma; (viii) Thyroid cancer; (ix) Atrial myxoma; (x) Breast cancer; (xi) Ovarian cancer; (xii) Melanoma; (xiii) Basal cell carcinoma	(i) 1 (5.9%); (ii) 2 (11.8%); (iii) 1 (5.9%); (iv) 3 (17.6%); (v) 2 (11.8%); (vi) 1 (5.9%); (vii) 1 (5.9%); (viii) 1 (5.9%); (ix) 1 (5.9%); (x) 1 (5.9%); (xi) 1 (5.9%); (xii) 1 (5.9%); (xiii) 1 (5.9%)

: number of patients.